Literature DB >> 27457520

Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism.

Min Jia1, Trygve Andreassen2, Lasse Jensen3, Tone Frost Bathen4, Indranil Sinha5, Hui Gao5, Chunyan Zhao5, Lars-Arne Haldosen5, Yihai Cao6, Leonard Girnita7, Siver Andreas Moestue4, Karin Dahlman-Wright1.   

Abstract

Estrogen receptor α (ERα) is a key regulator of breast growth and breast cancer development. Here, we report how ERα impacts these processes by reprogramming metabolism in malignant breast cells. We employed an integrated approach, combining genome-wide mapping of chromatin-bound ERα with estrogen-induced transcript and metabolic profiling, to demonstrate that ERα reprograms metabolism upon estrogen stimulation, including changes in aerobic glycolysis, nucleotide and amino acid synthesis, and choline (Cho) metabolism. Cho phosphotransferase CHPT1, identified as a direct ERα-regulated gene, was required for estrogen-induced effects on Cho metabolism, including increased phosphatidylcholine synthesis. CHPT1 silencing inhibited anchorage-independent growth and cell proliferation, also suppressing early-stage metastasis of tamoxifen-resistant breast cancer cells in a zebrafish xenograft model. Our results showed that ERα promotes metabolic alterations in breast cancer cells mediated by its target CHPT1, which this study implicates as a candidate therapeutic target. Cancer Res; 76(19); 5634-46. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27457520     DOI: 10.1158/0008-5472.CAN-15-2910

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Effects of α-zearalenol on the metabolome of two breast cancer cell lines by 1H-NMR approach.

Authors:  Anna Chiara Nittoli; Susan Costantini; Angela Sorice; Francesca Capone; Roberto Ciarcia; Stefania Marzocco; Alfredo Budillon; Lorella Severino
Journal:  Metabolomics       Date:  2018-02-14       Impact factor: 4.290

Review 2.  Breast Cancer Metabolism.

Authors:  Jessica Tan; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

3.  c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer.

Authors:  Huan He; Indranil Sinha; Rongrong Fan; Lars-Arne Haldosen; Feifei Yan; Chunyan Zhao; Karin Dahlman-Wright
Journal:  Oncogene       Date:  2018-02-22       Impact factor: 9.867

4.  The E3 ligase COP1 promotes ERα signaling and suppresses EMT in breast cancer.

Authors:  Kateryna Shostak; Alain Chariot; Seng Chuan Tang; Quentin Lion; Olivier Peulen; Philippe Chariot; Arnaud Lavergne; Alice Mayer; Paula Allepuz Fuster; Pierre Close; Sebastian Klein; Alexandra Florin; Reinhard Büttner; Ivan Nemazanyy
Journal:  Oncogene       Date:  2021-10-29       Impact factor: 9.867

5.  The Metabolic Signature of AML Cells Treated With Homoharringtonine.

Authors:  Yulong Zhang; Na Li; Zhiguang Chang; Huabin Wang; Hanzhong Pei; Dengyang Zhang; Qi Zhang; Junbin Huang; Yao Guo; Yuming Zhao; Yihang Pan; Chun Chen; Yun Chen
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

6.  Expression and activation of nuclear hormone receptors result in neuronal differentiation and favorable prognosis in neuroblastoma.

Authors:  Muhammad Mushtaq; Judit Liaño-Pons; Lourdes Sainero-Alcolado; Aida Rodriguez-Garcia; Ye Yuan; Tong Liu; María Victoria Ruiz-Pérez; Susanne Schlisio; Oscar Bedoya-Reina; Marie Arsenian-Henriksson
Journal:  J Exp Clin Cancer Res       Date:  2022-07-19

7.  Expression of hormone receptors in oropharyngeal squamous cell carcinoma.

Authors:  Hesham Mohamed; Katri Aro; Lauri Jouhi; Antti Mäkitie; Satu Remes; Caj Haglund; Timo Atula; Jaana Hagström
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-26       Impact factor: 2.503

8.  The Heterogeneity of Breast Cancer Metabolism.

Authors:  Jessica Tan; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.

Authors:  Jianbo Zhang; Chen Zhou; Huimin Jiang; Lin Liang; Wen Shi; Quansheng Zhang; Peiqing Sun; Rong Xiang; Yue Wang; Shuang Yang
Journal:  Cell Death Dis       Date:  2017-04-06       Impact factor: 8.469

10.  Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.

Authors:  Simeng Wen; Yundong He; Liewei Wang; Jun Zhang; Changyi Quan; Yuanjie Niu; Haojie Huang
Journal:  Oncogene       Date:  2020-09-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.